Literature DB >> 36247901

Clinical Profile and Treatment Outcomes of Hypermanganesemia with Dystonia 1 and 2 among 27 Indian Children.

Divyani Garg1, Sangeetha Yoganathan2, Uzma Shamim3, Kshitij Mankad4, Parveen Gulati5, Vincenzo Bonifati6, Abhijeet Botre7, Umesh Kalane8, Arushi Gahlot Saini9, Naveen Sankhyan9, Kavita Srivastava10, Vykuntaraju K Gowda11, Monica Juneja12, Mahesh Kamate13, Hansashree Padmanabha14, Debasis Panigrahi15, Shaila Pachapure16, Vrajesh Udani17, Atin Kumar18, Sanjay Pandey19, Maya Thomas2, Sumita Danda20, Shaikh Atif Iqbalahmed2, Annadurai Subramanian21, Harish Pemde22, Varinder Singh22, Mohammed Faruq3, Suvasini Sharma22.   

Abstract

Background: Hypermanganesemia with dystonia 1 and 2 (HMNDYT1 and 2) are rare, inherited disorders of manganese transport.
Objectives: We aimed to describe clinical, laboratory features, and outcomes among children with HMNDYT.
Methods: We conducted a retrospective multicenter study involving tertiary centers across India. We enrolled children between 1 month to 18 years of age with genetically confirmed/clinically probable HMNDYT. Clinical, laboratory profile, genetic testing, treatment details, and outcomes scored by treating physicians on a Likert scale were recorded.
Results: We enrolled 27 children (19 girls). Fourteen harbored SLC30A10 mutations; nine had SLC39A14 mutations. The SLC39A14 cohort had lower median age at onset (1.3 [interquartile range (IQR), 0.7-5.5] years) versus SLC30A10 cohort (2.0 [IQR, 1.5-5.1] years). The most frequent neurological features were dystonia (100%; n = 27), gait abnormality (77.7%; n = 21), falls (66.7%; n = 18), and parkinsonism (59.3%; n = 16). Median serum manganese (Mn) levels among SLC39A14 (44.9 [IQR, 27.3-147.7] mcg/L) cohort were higher than SLC30A10 (29.4 [17.1-42.0] mcg/L); median hemoglobin was higher in SLC30A10 (16.3 [IQR, 15.2-17.5] g/dL) versus SLC39A14 cohort (12.5 [8.8-13.2] g/dL). Hepatic involvement and polycythaemia were observed exclusively in SLC30A10 variants. A total of 26/27 children underwent chelation with disodium calcium edetate. Nine demonstrated some improvement, three stabilized, two had marked improvement, and one had normalization. Children with SLC39A14 mutations had poorer response. Two children died and nine were lost to follow-up. Conclusions: We found female predominance. Children with SLC39A14 mutations presented at younger age and responded less favorably to chelation compared to SLC30A10 mutations. There is emerging need to better define management strategies, especially in low resource settings.
© 2022 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  cirrhosis; dystonia; manganese; parkinsonism

Year:  2022        PMID: 36247901      PMCID: PMC9547147          DOI: 10.1002/mdc3.13516

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  29 in total

1.  Autosomal-recessive iron deficiency anemia, dystonia and hypermanganesemia caused by new variant mutation of the manganese transporter gene SLC39A14.

Authors:  Adel Zeglam; Abdusalam Abugrara; Mariam Kabuka
Journal:  Acta Neurol Belg       Date:  2018-09-19       Impact factor: 2.396

2.  Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease.

Authors:  Marialuisa Quadri; Antonio Federico; Tianna Zhao; Guido J Breedveld; Carla Battisti; Cathérine Delnooz; Lies-Anne Severijnen; Lara Di Toro Mammarella; Andrea Mignarri; Lucia Monti; Antioco Sanna; Peng Lu; Francesca Punzo; Giovanni Cossu; Rob Willemsen; Fabrizio Rasi; Ben A Oostra; Bart P van de Warrenburg; Vincenzo Bonifati
Journal:  Am J Hum Genet       Date:  2012-02-16       Impact factor: 11.025

3.  Neurologic manifestations in welders with pallidal MRI T1 hyperintensity.

Authors:  K A Josephs; J E Ahlskog; K J Klos; N Kumar; R D Fealey; M R Trenerry; C T Cowl
Journal:  Neurology       Date:  2005-05-11       Impact factor: 9.910

4.  Up-regulation of the manganese transporter SLC30A10 by hypoxia-inducible factors defines a homeostatic response to manganese toxicity.

Authors:  Chunyi Liu; Thomas Jursa; Michael Aschner; Donald R Smith; Somshuvra Mukhopadhyay
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-31       Impact factor: 11.205

5.  Hypothyroidism induced by loss of the manganese efflux transporter SLC30A10 may be explained by reduced thyroxine production.

Authors:  Chunyi Liu; Steven Hutchens; Thomas Jursa; William Shawlot; Elena V Polishchuk; Roman S Polishchuk; Beth K Dray; Andrea C Gore; Michael Aschner; Donald R Smith; Somshuvra Mukhopadhyay
Journal:  J Biol Chem       Date:  2017-08-31       Impact factor: 5.157

6.  Hypermanganesemia with dystonia, polycythemia and cirrhosis in 10 patients: Six novel SLC30A10 mutations and further phenotype delineation.

Authors:  M S Zaki; M Y Issa; H M Elbendary; H El-Karaksy; H Hosny; C Ghobrial; A El Safty; A El-Hennawy; A Oraby; L Selim; M S Abdel-Hamid
Journal:  Clin Genet       Date:  2018-02-11       Impact factor: 4.438

7.  Hepatic cirrhosis, dystonia, polycythaemia and hypermanganesaemia--a new metabolic disorder.

Authors:  Karin Tuschl; Philippa B Mills; Howard Parsons; Marian Malone; Darren Fowler; Maria Bitner-Glindzicz; Peter T Clayton
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.982

8.  A case of dystonia with polycythemia and hypermanganesemia caused by SLC30A10 mutation: a treatable inborn error of manganese metabolism.

Authors:  Azita Tavasoli; Khadije Arjmandi Rafsanjani; Saba Hemmati; Marziyeh Mojbafan; Elham Zarei; Soudabeh Hosseini
Journal:  BMC Pediatr       Date:  2019-07-09       Impact factor: 2.125

9.  Dystonia with brain manganese accumulation resulting from SLC30A10 mutations: a new treatable disorder.

Authors:  Maria Stamelou; Karin Tuschl; W K Chong; Andrew K Burroughs; Philippa B Mills; Kailash P Bhatia; Peter T Clayton
Journal:  Mov Disord       Date:  2012-08-23       Impact factor: 10.338

10.  Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood-onset parkinsonism-dystonia.

Authors:  Karin Tuschl; Esther Meyer; Leonardo E Valdivia; Ningning Zhao; Chris Dadswell; Alaa Abdul-Sada; Christina Y Hung; Michael A Simpson; W K Chong; Thomas S Jacques; Randy L Woltjer; Simon Eaton; Allison Gregory; Lynn Sanford; Eleanna Kara; Henry Houlden; Stephan M Cuno; Holger Prokisch; Lorella Valletta; Valeria Tiranti; Rasha Younis; Eamonn R Maher; John Spencer; Ania Straatman-Iwanowska; Paul Gissen; Laila A M Selim; Guillem Pintos-Morell; Wifredo Coroleu-Lletget; Shekeeb S Mohammad; Sangeetha Yoganathan; Russell C Dale; Maya Thomas; Jason Rihel; Olaf A Bodamer; Caroline A Enns; Susan J Hayflick; Peter T Clayton; Philippa B Mills; Manju A Kurian; Stephen W Wilson
Journal:  Nat Commun       Date:  2016-05-27       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.